| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | -0.0087 | 0.8 |